Among patients with advanced colorectal cancer (CRC), a small subgroup seems to benefit from the epidermal growth factor receptor (EGFR) inhibitor, cetuximab (Cunningham et al, 2004; Saltz et al, 2004). Here, EGFR is linked to colorectal cancer.